164 related articles for article (PubMed ID: 28185527)
1. Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphoma.
Falay O; Öztürk E; Bölükbaşı Y; Gümüş T; Örnek S; Özbalak M; Çetiner M; Demirkol O; Ferhanoğlu B
Leuk Lymphoma; 2017 May; 58(5):1114-1122. PubMed ID: 28185527
[TBL] [Abstract][Full Text] [Related]
2. FDG positron emission tomography/computerized tomography features of bleomycin-induced pneumonitis.
Kirsch J; Arrossi AV; Yoon JK; Wu G; Neumann DR
J Thorac Imaging; 2006 Aug; 21(3):228-30. PubMed ID: 16915070
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin's disease--a useful tool for monitoring pulmonary toxicity and disease activity.
Buchler T; Bomanji J; Lee SM
Haematologica; 2007 Nov; 92(11):e120-1. PubMed ID: 18024389
[TBL] [Abstract][Full Text] [Related]
4. Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in the early diagnosis of asymptomatic bleomycin-induced pneumonitis.
Connerotte T; Lonneux M; de Meeûs Y; Hermans C; Vekemans MC; Ferrant A; Van Den Neste E
Ann Hematol; 2008 Nov; 87(11):943-5. PubMed ID: 18443792
[No Abstract] [Full Text] [Related]
5. Bleomycin Toxicity - Findings on FDG PET CT.
Mufty S; Razi M; Hassan A
J Pak Med Assoc; 2021 Sep; 71(9):2287-2288. PubMed ID: 34580536
[TBL] [Abstract][Full Text] [Related]
6. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.
Mesguich C; Cazeau AL; Bouabdallah K; Soubeyran P; Guyot M; Milpied N; Bordenave L; Hindié E
Br J Haematol; 2016 Nov; 175(4):652-660. PubMed ID: 27539369
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma.
Ngeow J; Tan IB; Kanesvaran R; Tan HC; Tao M; Quek R; Lim ST
Ann Hematol; 2011 Jan; 90(1):67-72. PubMed ID: 20676640
[TBL] [Abstract][Full Text] [Related]
8. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
9. Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.
Gandikota N; Hartridge-Lambert S; Migliacci JC; Yahalom J; Portlock CS; Schöder H
Cancer; 2015 Jun; 121(12):1985-92. PubMed ID: 25739719
[TBL] [Abstract][Full Text] [Related]
10. Bleomycin induced flagellate erythema: Revisiting a unique complication.
Biswas A; Chaudhari PB; Sharma P; Singh L; Julka PK; Sethuraman G
J Cancer Res Ther; 2013; 9(3):500-3. PubMed ID: 24125992
[TBL] [Abstract][Full Text] [Related]
11. Increased pulmonary FDG uptake in bleomycin-associated pneumonitis.
von Rohr L; Klaeser B; Joerger M; Kluckert T; Cerny T; Gillessen S
Onkologie; 2007 Jun; 30(6):320-3. PubMed ID: 17551256
[TBL] [Abstract][Full Text] [Related]
12. Thymic 18F-fluorodeoxyglucose uptake on positron emission tomography scanning after doxorubicin, bleomycin, vincristin and dacarbazine chemotherapy and highly-active antiretroviral therapy in HIV-associated Hodgkin's disease in an adult.
Lee SM; Buchler T; Bomanji J; Ramsay A; Edwards SG
AIDS; 2008 Jan; 22(1):159-60. PubMed ID: 18090408
[No Abstract] [Full Text] [Related]
13. Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?
Abou Yehia Z; Mikhaeel GN; Smith G; Pinnix CC; Milgrom SA; Tang C; Jiang W; Fanale MA; Oki Y; Shank JH; Horace T; Reddy J; Akhtari M; Gunther JR; Suki T; Allen PK; Turner S; Mawlawi O; Dabaja BS
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):951-958. PubMed ID: 27742539
[TBL] [Abstract][Full Text] [Related]
14. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
[TBL] [Abstract][Full Text] [Related]
15. Lungs on fire.
Batra S; Vaid AK; Bhargava R; Gupta S
BMJ Case Rep; 2013 Jun; 2013():. PubMed ID: 23814214
[TBL] [Abstract][Full Text] [Related]
16. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
[TBL] [Abstract][Full Text] [Related]
17. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced pneumonitis detected earlier by 18F-FDG-PET than by high-resolution CT: a case report with non-Hodgkin's lymphoma.
Yamane T; Daimaru O; Ito S; Nagata T; Yoshiya K; Fukaya N; Ito S; Imai T; Uchida H
Ann Nucl Med; 2008 Oct; 22(8):719-22. PubMed ID: 18982476
[TBL] [Abstract][Full Text] [Related]
19. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous pneumomediastinum caused by bleomycin-induced pneumonitis.
Frusch N; Servais S; De Prijck B; Corhay JL; Beguin Y; Louis R; Duysinx B
Acta Clin Belg; 2012; 67(5):370-1. PubMed ID: 23189547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
